SEC Filing | Tandem Diabetes Care

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cajigas John

(Last)

(First)

(Middle)

C/O TANDEM DIABETES CARE, INC.,

11045 ROSELLE STREET

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/13/2013

3. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
CHIEF FINANCIAL OFFICER

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	14,323	I	See footnote⁽¹⁾
Common Stock⁽²⁾	8,952	I	See footnote⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B Preferred Stock	⁽³⁾	⁽⁴⁾	Common Stock	2,585	0.00	I	See footnote⁽¹⁾
Series C Preferred Stock	⁽³⁾	⁽⁴⁾	Common Stock	2,236	0.00	I	See footnote⁽¹⁾
Series D Preferred Stock	⁽³⁾	⁽⁴⁾	Common Stock	13,367	0.00	I	See footnote⁽¹⁾
Preferred Stock Warrant	⁽⁵⁾	08/31/2021	Series D Preferred Stock⁽⁶⁾	1,416⁽⁶⁾	4.4⁽⁶⁾	I	See footnote⁽¹⁾
Preferred Stock Warrant	⁽⁵⁾	05/25/2022	Series D Preferred Stock⁽⁷⁾	3,636⁽⁷⁾	4.4⁽⁷⁾	I	See footnote⁽¹⁾
Preferred Stock Warrant	⁽⁵⁾	08/21/2022	Series D Preferred Stock⁽⁸⁾	3,710⁽⁸⁾	4.4⁽⁸⁾	I	See footnote⁽¹⁾
Incentive Stock Option⁽⁹⁾	⁽¹⁰⁾	⁽¹¹⁾	Common Stock	119,360	1.11	D

Explanation of Responses:

1. The securities are held by the John Cajigas and Mary E. Cajigas Family Trust, dated 8/11/2005.

2. Restricted stock issued pursuant to the Issuer's Tandem Diabetes Care, Inc. 2006 Stock Incentive Plan. These shares vested as to 25% on 10/20/2012 and continue to vest in 36 equal monthly installments thereafter, and will automatically vest in full upon consummation of the Issuer's initial public offering.

3. The securities are immediately convertible.

4. The expiration date is not relevant to the conversion of these securities.

5. The warrants are immediately exercisable.

6. Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 845 shares of the Issuer's common stock at an exercise price of $7.37 per share.

7. Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 2,169 shares of the Issuer's common stock at an exercise price of $7.37 per share.

8. Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 2,214 shares of the Issuer's common stock at an exercise price of $7.37 per share.

9. Granted pursuant to the Issuer's Tandem Diabetes Care, Inc. 2006 Stock Incentive Plan.

10. The date of grant of the option was 4/23/2013. All shares subject to the option will vest in 24 equal monthly installments commencing on 4/23/2013.

11. The expiration date for these options is 10 years from the date of grant.

Remarks:

	/s/ David B. Berger, Attorney-in-Fact for John Cajigas	11/13/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY
	The undersigned hereby constitutes and appoints David B. Berger, John Cajigas,
Leigh Vosseller and Bruce Feuchter, or any of them signing individually, the
undersigned's true and lawful attorney-in-fact to:
(1)	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer of Tandem Diabetes Care, Inc. (the "Company"), Forms 3, 4 and 5 in
accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act") and the rules and regulations thereunder;
(2)	do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute any such Forms 3, 4s and
5s and timely file such form with the SEC and any stock exchange or similar
authority; and
(3)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
	The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform each and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution and revocation,
hereby ratifying and confirming all that each such attorney-in-fact, or each
such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to
be done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that each of the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
	The undersigned agrees that each such attorney-in-fact may rely entirely on
information furnished orally or in writing by the undersigned to each such
attorney-in-fact.  The undersigned also agrees to indemnify and hold harmless
the Company and each such attorney-in-fact against any losses, claims, damages
or liabilities (or actions in these respects) that arise out of or are based on
any untrue statement or omission of necessary facts in the information provided
by the undersigned to such attorney-in-fact for purposes of executing,
acknowledging, delivering and filing Forms 3, 4s or 5s (including amendments
thereto) and agrees to reimburse the Company and each such attorney-in-fact for
any legal or other expenses reasonably incurred in connection with investigating
or defending against any such loss, claim, damage, liability or action.
	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4s and 5s with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 6th day of November 2013.


					/s/ John Cajigas